Emerging cytoprotective peptide therapies for stroke

Bruno P. Melonia Perron Institute for Neurological and Translational Science, Nedlands, Australia;b Department of Neurosurgery, Sir Charles Gairdner Hospital, QEII Medical Centre, Nedlands, Western Australia, Australia;c Centre for Neuromuscular and Neurological Disorders, The University of Western Australia, Nedlands, Western Australia, AustraliaCorrespondence[email protected]
View further author information

David J. Blackera Perron Institute for Neurological and Translational Science, Nedlands, Australia;b Department of Neurosurgery, Sir Charles Gairdner Hospital, QEII Medical Centre, Nedlands, Western Australia, Australia;d Department of Neurology, Sir Charles Gairdner Hospital, QEII Medical Centre, Nedlands, Western Australia, AustraliaView further author information

Frank L. Mastagliaa Perron Institute for Neurological and Translational Science, Nedlands, Australia;b Department of Neurosurgery, Sir Charles Gairdner Hospital, QEII Medical Centre, Nedlands, Western Australia, AustraliaView further author information

Neville W. Knuckeya Perron Institute for Neurological and Translational Science, Nedlands, Australia;b Department of Neurosurgery, Sir Charles Gairdner Hospital, QEII Medical Centre, Nedlands, Western Australia, Australia;c Centre for Neuromuscular and Neurological Disorders, The University of Western Australia, Nedlands, Western Australia, AustraliaView further author information

Click to increase image sizeClick to decrease image size

Declaration of interest

N Knuckey and B Meloni are named inventors on several patents for the use of CARPs as therapeutic agents. In addition, N Knuckey, B Meloni. and D Blacker. are shareholders in Argenica Therapeutics, which is a company developing R18 as a stroke therapeutic. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or conflict with the subject matter or materials discussed in this manuscript apart from those disclosed Citation10.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose Citation6.

Additional information

Funding

This paper was not funded.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Emerging cytoprotective peptide therapies for stroke

Information for

Open access

Opportunities

Help and information

Emerging cytoprotective peptide therapies for stroke

Declaration of interest

Reviewer disclosures

Additional information

Funding

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature